Association of statin use with risk of Gleason score-specific prostate cancer: A hospital-based cohort study

Kai Wang1,2 | Travis A. Gerke3 | Xinguang Chen1 | Mattia Prosperi1

1Department of Epidemiology, University of Florida, Gainesville, Florida
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
3Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida

Correspondence
Kai Wang, Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, MA 02115.
Email: nhkwa@channing.harvard.edu

Mattia Prosperi, Department of Epidemiology, University of Florida, 2004 Mowry Road, Gainesville, FL 32610.
Email: m.prosperi@ufl.edu

Funding information
None.

Abstract
Background: Conflicting evidence suggests that statins act chemopreventively against prostate cancer (PCa). Whether the association of statin use with PCa risk is Gleason score-dependent, time-, dose-response is not well studied.

Methods: We conducted a cohort study at a tertiary hospital in the Southeastern US using longitudinal data of electronic medical records (EMR) from 1994 to 2016. Only cancer-free men aged >18 years at baseline with follow-up time of ≥12 months were included. Time-dependent Cox proportional hazards regression was used to estimate adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs).

Results: Among 13,065 men, 2,976 were diagnosed with PCa over median follow-up of 6.6 years. Statin use was associated with lower risk of both Gleason low- (score <7: aHR, 0.85; 95% CI, 0.74-0.96) and high-grade PCa (score ≥7: aHR, 0.54; 95% CI, 0.42-0.69). The protective association was observed only when statins had been used for a relatively longer duration (≥11 months) or higher dose (≥121 defined daily doses), and were more pronounced for PCa of higher Gleason score (<7: aHR, 0.85, 95% CI, 0.74-0.96; 7 [3 + 4]: aHR, 0.62, 95% CI, 0.43-0.90; 7 [4 + 3]: aHR, 0.49, 95% CI, 0.29-0.82; 8: aHR, 0.60, 95% CI, 0.37-0.96; 9-10: aHR, 0.24, 95% CI, 0.11-0.54). Lipophilic statins (aHR, 0.83; 95% CI, 0.72-0.95) might be more protective than hydrophilic statins (aHR, 0.91, 95% CI, 0.63-1.33) against PCa.

Conclusion: Statin use might be associated with reduced PCa risk only when used for a relatively longer duration, and the risk reduction was higher for PCa of higher Gleason score.

KEYWORDS
dose-response, Gleason score, lipophilicity, prostate cancer, statins

1 | INTRODUCTION

Prostate cancer (PCa) is the most commonly diagnosed solid organ cancer and the second leading cause of cancer death among men in the US.1 PCa is often a slowly growing cancer with a long latency period of up to 15 to 20 years.2 Autopsy studies showed that a quarter of men in 40s and up to 40% of men aged 80 years or older harbor indolent local malignant lesions of the prostate.3 The high lifetime incidence and slow rate in PCa development make PCa an attractive target for chemoprevention.

Statins are a family of cholesterol-lowering medications with documented effectiveness in preventing cardiovascular
disease. The past 15 years have seen a dramatic increase in the prevalence of statin use, and statins are among the most prescribed medications in both the US and worldwide. Lowering serum and tissue cholesterol is thought to bring about a disruption in cellular lipid rafts, leading to reduced raft-dependent signaling and cell proliferation. Therefore, statins may play a chemopreventive role in reducing the risk of carcinogenesis, including prostate carcinogenesis. Because PCa is highly incident and few preventive strategies currently exist, elucidation of a benefit of statins in preventing PCa could confer a considerable significance in public health. Clarifying the statin-PCa association may also cast light to elucidate the steroid hormone mechanism connecting metabolic disorders with prostate carcinogenesis.

Statin use has been reported to be negatively correlated with advanced PCa risk, but evidence for the associations of statin use with overall PCa remains mixed and with Gleason score-specific PCa is rare. Reasons for such a varying observation are not clarified but may result from a detection bias (“healthy user bias”). Because statin users are in a higher need of health services than those without using the medication, they may have more chances to take a prostate-specific antigen (PSA) testing and thus are more likely to detect subclinical PCa. Therefore, a lack of statistical adjustment for PSA testing and PCa grade would considerably limit the study power on statins and PCa risk. Even after attempting to control for the potential healthy user bias, several other questions remain unclear: does the relationship between statin use and PCa risk have duration- and/or dose-response properties; is statin use associated with PCa risk in a Gleason score-specific manner; and does statin lipophilicity affect the association? To clarify these important questions, further studies on statin and PCa are needed.

Therefore, we used a large hospital-based longitudinal dataset to examine the association of statin use with PCa risk and specific Gleason score at diagnosis. Further, we explored whether the relationship is duration- and/or dose-responsive and statin lipophilicity-dependent.

2 METHODS

2.1 Study population

A cohort study was conducted at a tertiary hospital affiliated to a university in the Southeastern US based on electronic medical records (EMR) data. This large-scale health database was administered and provided by a professional Clinical and Translational Science Institute (CTSI) at the hospital and university, and collects and organizes information across all the university’s clinical and research institutes located across the whole state. We included patients with at least one visit of the urologic clinic because of any prostatic conditions. International Classification of Disease, Ninth Revision (ICD-9) codes (Table S1) were used to derive the data. For each included man, we then extracted all his medical records of previous and subsequent hospital visits throughout all medical departments (not limited to the urologic clinic). Data of demographics, lab results, medical diagnoses, medication prescriptions, and other clinical information were linked by a de-identified patient ID. For each participant, the time of his first recorded hospital visit served as baseline and subsequent hospital visits served as follow-ups. We only analyzed data measured before or at the time of PCa diagnosis. For men not diagnosed with PCa, the most recent hospital visit served as the time point of censoring. We excluded men 1) aged ≤18 years at baseline (n = 27) or 2) with a follow-up duration of <12 months (n = 6993), resulting in the exclusion of 7020 men (4591 PCa and 2429 non-PCa). We included a total of 13,065 men in the analysis, with the medical records ranging from November 1994 to January 2016.

This study has been performed in accordance with the Declaration of Helsinki. The research protocol was approved by the institutional review board at the University of Florida.

2.2 Assessment of statin exposure

We included all types of statins on the US market. These statins comprised of hydrophilic and lipophilic statins, with the former included rosuvastatin and pravastatin, and the latter included fluvastatin, lovastatin, simvastatin, atorvastatin, and cerivastatin.

We created statin use as a time-dependent variable. Men were treated as statin nonusers up until the time when they were prescribed with statins for the first time, and as users thereafter for the remaining follow-up time. Therefore, participants contributed the person-time before their first statin prescription into the statin nonuser group, and after that time point into user group. We analyzed statin use in three time-dependent variables: binary status (user or nonuser), cumulative duration of statin use, and cumulative dose of statin use. By analyzing cumulative duration and dose, we aimed to explore whether statins associate with the risk of PCa in a time- or dose-response form. In a time-dependent form, we created the cumulative duration by summing the months since the prior statin prescription for every follow-up (hospital visit). We then categorized this variable by quintiles (1-10, 11-29, 30-60, 61-101, and 102-239 months) among statin users throughout all follow-ups. We then evaluated the cumulative dose of statin by units of defined daily dose (DDD). We used the DDD of simvastatin in 20-mg formulation as the reference, and used the DDDs of the other statins to convert them to 20-mg simvastatin-equivalent doses. Likewise, cumulative dose was calculated by summing all DDDs for each follow-up, and categorized by quintiles among statin users (5-40, 41-120, 121-240, 241-615, and 616-38750 DDDs).
2.3 | Outcome ascertainment

The outcome of interest was newly diagnosed PCa. PCa diagnosis was extracted from EMR database using ICD-9 code for malignant neoplasm of prostate of 185 and carcinoma in situ of prostate of 233.4. We also derived the specific Gleason score for all PCa diagnosis. Due to the limited case number in some Gleason score categories (7 [3 + 4]: 259 cases; 7 [4 + 3]: 169 cases; ≥8:240 cases) and in order to have a better statistical power, in the main analysis, we merged the three categories of 7 (3 + 4), 7 (4 + 3), and ≥8 and referred to them totally as high-grade PCa. PCa with Gleason score of <7 was referred to as low-grade PCa.

2.4 | Covariates

We also assessed potential confounders for the association between statin use and PCa risk, including age (years), race (white, black, and other), smoking status (current, former, and never), body mass index (BMI) (<18.5, 18.5 to <25, 25 to <30, and ≥30 kg/m²), PCa family history; history of diabetes, cardiovascular disease, chronic kidney disease, hyperlipidemia, hypertension, and benign prostatic disease; medication use of aspirin, angiotensin-converting enzyme inhibitor, insulin, vitamin E/multivitamin, finasteride, metformin, testosterone, selenium; PSA level (<4, 4-10, and >10 ng/mL) and cumulative times of PSA testing.

2.5 | Statistical analysis

Characteristics of the study sample at baseline (time window of 1 month) were assessed using descriptive statistics, including median, interquartile range (IQR), and proportions. Chi-squared test for categorical variables and Wilcoxon rank-sum test for continuous variables were used to compare baseline characteristics of the cohort grouped by statin use throughout the study period. We estimated hazard ratios (HRs) and 95% confidence intervals (CI) for overall, low-, and high-grade PCa using time-dependent Cox proportional hazards regression models with participants’ age as the time metric. We evaluated statin use (use vs no use), cumulative duration of statin use (quintiles vs no use), and cumulative dose of statin use (quintiles vs no use) as time-dependent variables, which were updated at the end of each calendar year during follow-up. Time at risk began to accrue at baseline and ended on the date of PCa diagnosis or censoring, whichever occurred first. Linear trend of cumulative statin duration and dose in relation to PCa risk were examined by entering the quintiles of these variables in continuous form. We adjusted for baseline covariates with potential to confound the statin-PCa association (listed in Table 1). Diagnosis of cardiovascular disease (CVD), as a main clinical reason for statin prescription, together with cumulative number of PSA testing was entered as time-dependent covariate. The proportional hazards assumption was tested by adding an interaction term of participant age and statin use to the Cox regression models. The term was not statistically significant by the likelihood ratio test, indicating no violation of the assumption.

We further stratified the analyses by low-/high-PCa Gleason grade (Gleason score <7 and ≥7), specific Gleason score (<7, 7 (3 + 4), 7 (4 + 3), 8, 9-10), and statin lipophilicity. In the analysis of statin lipophilicity, statin users were classified by the following three categorical variables: only used lipophilic statins, only used hydrophilic statins, and used both lipophilic and hydrophilic statins.

2.6 | Sensitivity analysis

We also stratified the analyses by baseline PSA level (<4 ng/mL, ≥4 ng/mL, and unknown), CVD diagnosis (yes/no), and combination of statin and aspirin use during follow-up (no use of statins or aspirin, only statins, only aspirin, and both statins and aspirin).

We used R 3.1.1 (R Development Core Team 2014) for the data analysis. All P values were two-tailed and P < .05 was statistically significant.

3 | RESULTS

3.1 | Characteristics of study participants

Among the 13 065 men included, median (IQR) age at baseline was 62 (53, 71) years. Over a total of 94 801.6 person-years follow-up (median 6.6 years), 2976 were diagnosed with PCa, among which 2308 were low-grade (Gleason score <7) and 668 were high-grade (Gleason score ≥7). Specifically, 259 were of Gleason score 7 (3 + 4), 169 were of 7 (4 + 3), 136 were of 8, and 104 were of 9-10. Of the total sample, 3839 (29.4%, 3839/13065) used statins during the study period. Baseline characteristics by statin use throughout all follow-ups are listed in Table 1.

3.2 | Association of statin use with risk of overall PCa

In the fully adjusted model, statin use was significantly associated with decreased risk of overall PCa (adjusted HR [aHR], 0.80; 95% CI, 0.71-0.90), compared with no statin use. A decreasing pattern in PCa risk was observed with increasing cumulative duration (≥102 months: aHR, 0.47; 95% CI, 0.34-0.67; P<.001) and cumulative dose (≥616 DDDs: aHR, 0.66; 95% CI, 0.50-0.88; P<.001) of statin use. Of note, the protective association of statin with PCa was only observed with a relatively longer duration...
| Characteristic                   | Entire cohort (n = 13 065) | Nonstatin user (n = 9226) | Statin users (n = 3839) | P value\(^a\) |
|---------------------------------|-----------------------------|---------------------------|------------------------|---------------|
|                                | No.   | %     | No.   | %    | No.   | %    |            |
| Age, years                      |       |       |       |       |       |       |            |
| Median                          | 62    | 61    | 65    | <.001|
| Interquartile range             | 53-71 | 51-70 | 57-72 | <.001|
| Race                            |       |       |       |       |       |       |            |
| White                           | 6207  | 47.5  | 4308  | 46.7  | 1899  | 49.5  | .004       |
| Black                           | 1057  | 8.1   | 710   | 7.7   | 347   | 9.0   | .010       |
| Other                           | 324   | 2.5   | 260   | 2.8   | 64    | 1.7   | <.001      |
| Unknown                         | 5477  | 41.9  | 3948  | 42.8  | 1529  | 39.8  | .002       |
| Smoking status                  |       |       |       |       |       |       |            |
| Current smoker                  | 602   | 4.6   | 395   | 4.3   | 207   | 5.4   | .006       |
| Former smoker                   | 3105  | 23.8  | 2000  | 21.7  | 1105  | 28.8  | <.001      |
| Never smoke                     | 2968  | 22.7  | 2265  | 24.5  | 703   | 18.3  | <.001      |
| Unknown                         | 6390  | 48.9  | 4566  | 49.5  | 1824  | 47.5  | .039       |
| Body mass index, kg/m\(^2\)    |       |       |       |       |       |       |            |
| <18.5                           | 84    | 0.6   | 39    | 0.4   | 45    | 1.2   | <.001      |
| 18.5 to <25                     | 962   | 7.4   | 487   | 5.3   | 475   | 12.4  | <.001      |
| 25 to <30                       | 1338  | 10.2  | 571   | 6.2   | 767   | 20.0  | <.001      |
| ≥30                             | 1334  | 10.2  | 560   | 6.1   | 774   | 20.2  | <.001      |
| Unknown                         | 9347  | 71.5  | 7569  | 82.0  | 1778  | 46.3  | <.001      |
| Prostate-specific antigen, ng/mL|       |       |       |       |       |       |            |
| <4                              | 7206  | 55.2  | 5087  | 55.1  | 2119  | 55.2  | .951       |
| 4-10                            | 963   | 7.4   | 710   | 7.7   | 253   | 6.6   | .028       |
| >10                             | 324   | 2.5   | 261   | 2.8   | 63    | 1.6   | <.001      |
| Unknown                         | 4572  | 35.0  | 3168  | 34.3  | 1404  | 36.6  | .015       |
| Family history of prostate cancer| 225  | 1.7   | 183   | 2.0   | 42    | 1.1   | <.001      |
| Comorbidities                   |       |       |       |       |       |       |            |
| Hypertension                    | 4609  | 35.3  | 2739  | 29.7  | 1870  | 48.7  | <.001      |
| Hyperlipidemia                  | 2972  | 22.8  | 1601  | 17.4  | 1371  | 35.7  | <.001      |
| Benign prostatic diseases       | 2790  | 21.4  | 1912  | 20.7  | 878   | 22.9  | <.001      |
| Atherosclerotic cardiovascular disease | 2579  | 19.7  | 1109  | 12.0  | 1470  | 38.3  | <.001      |
| Diabetes                        | 1625  | 12.4  | 849   | 9.2   | 776   | 20.2  | <.001      |
| Chronic kidney disease          | 477   | 3.7   | 247   | 2.7   | 230   | 6.0   | <.001      |
| Histories of medication         |       |       |       |       |       |       |            |
| Aspirin                         | 1738  | 13.3  | 632   | 6.9   | 1106  | 28.8  | <0.001     |
| ACE inhibitor                   | 1115  | 8.5   | 400   | 4.3   | 715   | 18.6  | <.001      |
| Insulin                         | 1102  | 8.4   | 476   | 5.2   | 626   | 16.3  | <.001      |
| Vitamin E/multivitamin          | 809   | 6.2   | 403   | 4.4   | 406   | 10.6  | <.001      |
| Finasteride                     | 165   | 1.3   | 68    | 0.7   | 97    | 2.5   | <.001      |
| Metformin                       | 135   | 1.0   | 56    | 0.6   | 79    | 2.1   | <.001      |

(Continues)
(≥11 months) or higher dose (≥121 DDDs). A short-term statin use (1-10 months) was observed to be associated with an increased PCa risk (aHR, 1.88; 95% CI, 1.63-2.17) (Table 2; Figure 1).

### 3.3 Association of statin use with risk of grade-specific PCa

In PCa Gleason grade-stratified analysis, statin use was associated with decreased risk of both low-grade (aHR, 0.85; 95% CI, 0.74-0.96) and high-grade PCa (aHR, 0.54; 95% CI, 0.42-0.69), compared with no statin use. The risk of low-grade PCa decreased with both increasing duration (≥102 months: aHR, 0.39; 95% CI, 0.26-0.60; $P_{\text{trend}} < .001$) and dose (≥616 DDDs: aHR, 0.70; 95% CI, 0.52-0.94; $P_{\text{trend}} < .001$) of statin use. The protective association was only observed when statins were used for ≥30 months or ≥121 DDDs. A short-term statin use was associated with an increased low-grade PCa risk (≤10 months: aHR, 2.03; 95% CI, 1.73-2.37), but this risk increase was not found in statin cumulative dose

### Table 2 Association of statin use with risk of overall and Gleason grade-specific prostate cancer

| Statin exposure | Overall | Gleason 2-6 | Gleason 7-10 |
|-----------------|---------|-------------|--------------|
| No use of statins | 2453 | 1.00 | 1868 | 1.00 | 585 | 1.00 |
| Use of statins | 523 | 0.80 (0.71-0.90) | 440 | 0.85 (0.74-0.96) | 83 | 0.54 (0.42-0.69) |

| Cumulative duration, months | No of cases | HR (95% CI)$^a$ | No of cases | HR (95% CI)$^a$ | No of cases | HR (95% CI)$^a$ |
|-----------------------------|-------------|-----------------|-------------|-----------------|-------------|-----------------|
| Quint 1: 1-10 | 233 | 1.88 (1.63-2.17) | 211 | 2.03 (1.73-2.37) | 22 | 0.92 (0.59-1.44) |
| Quint 2: 11-29 | 126 | 0.77 (0.64-0.92) | 110 | 0.82 (0.67-1.00) | 16 | 0.45 (0.27-0.73) |
| Quint 3: 30-60 | 72 | 0.43 (0.34-0.55) | 55 | 0.42 (0.32-0.55) | 17 | 0.41 (0.25-0.66) |
| Quint 4: 61-101 | 57 | 0.46 (0.35-0.60) | 42 | 0.43 (0.32-0.59) | 15 | 0.47 (0.28-0.80) |
| Quint 5: 102-239 | 35 | 0.47 (0.34-0.67) | 22 | 0.39 (0.26-0.60) | 13 | 0.69 (0.39-1.20) |

$P_{\text{trend}} <0.001 <0.001 <0.001$

| Cumulative dose, DDD$^b$ | No of cases | HR (95% CI)$^a$ | No of cases | HR (95% CI)$^a$ | No of cases | HR (95% CI)$^a$ |
|--------------------------|-------------|-----------------|-------------|-----------------|-------------|-----------------|
| Quint 1: 5-40 | 171 | 0.97 (0.81-1.16) | 144 | 1.05 (0.86-1.27) | 27 | 0.63 (0.42-0.94) |
| Quint 2: 41-120 | 166 | 0.93 (0.78-1.11) | 136 | 0.95 (0.78-1.15) | 30 | 0.73 (0.49-1.10) |
| Quint 3: 121-240 | 74 | 0.69 (0.54-0.88) | 64 | 0.74 (0.57-0.97) | 10 | 0.38 (0.21-0.72) |
| Quint 4: 241-615 | 56 | 0.50 (0.38-0.66) | 48 | 0.54 (0.40-0.73) | 8 | 0.29 (0.14-0.59) |
| Quint 5: 616-38750 | 56 | 0.66 (0.50-0.88) | 48 | 0.70 (0.52-0.94) | 8 | 0.44 (0.22-0.88) |

$P_{\text{trend}} <0.001 <0.001 <0.001$

Abbreviations: CI, confidence interval; DDD, defined daily dose; HR, hazard ratio.

$^a$Using age as time metric in the models adjusted for race, family history of prostate cancer; baseline smoking status, body mass index, hypertension, hyperlipidemia, benign prostatic diseases, diabetes, chronic kidney disease, use of aspirin, angiotensin-converting enzyme inhibitors, insulin, vitamin E/multivitamin, finasteride, metformin, testosterone supplement, selenium, prostate-specific antigen level; as well as atherosclerotic cardiovascular disease and cumulative number of prostate-specific antigen tests as time-dependent variables.

$^b$Based on an equivalent dose of 20-mg simvastatin.
analysis (Table 2). For high-grade PCa, a decreased trend in the risk with increasing duration and dose of stain use was also observed, but no risk increase was found with low-duration or low-dose group (Table 2).

In Gleason score-stratified analysis, the statin use-associated PCa risk reduction was higher for PCa with a higher Gleason score (<7: aHR, 0.85; 95% CI, 0.74-0.96; 9-10: aHR, 0.24; 95% CI, 0.11-0.54) (Table 3).

### 3.4 Association of statin lipophilicity with PCa risk

When statins were categorized by lipophilicity, only lipophilic statins were associated with decreased PCa risk (overall PCa: aHR, 0.83; 95% CI, 0.72-0.95; high-grade PCa: aHR, 0.63; 95% CI, 0.48-0.83), whereas no significant association was observed of only hydrophilic statins.

**FIGURE 1** Risk of overall (A) and Gleason grade-specific prostate cancer (B and C) by cumulative duration and dose of statin use. 

\(^a\)Statin users stratified by quintiles of cumulative duration of statin use during the study period. 
\(^b\)Statin users stratified by quintiles of cumulative dose of statin use during the study period. 
\(^c\)From time-dependent Cox proportional hazards regression using age as time metric adjusting for race, family history of prostate cancer; baseline smoking status, body mass index, hypertension, hyperlipidemia, benign prostatic diseases, diabetes, chronic kidney disease, use of aspirin, angiotensin-converting enzyme inhibitors, insulin, vitamin E/multivitamin, finasteride, metformin, testosterone supplement, selenium, prostate-specific antigen level; as well as atherosclerotic cardiovascular disease and cumulative number of prostate-specific antigen tests as time-dependent variables.
or both lipophilic and hydrophilic statins with PCa risk (Table 4).

### 3.5 Sensitivity analyses

The statin use-associated PCa risk reduction was only observed among those with baseline PSA ≥4 ng/mL (Table S2), but the risk reduction was consistent across subgroups of baseline CVD diagnosis (Table S3). Prescriptions of statins and aspirin were highly correlated ($\chi^2 = 4128.6$, $P < .001$, agreement = 80.2%, $(7448 + 3024)/13065$). Compared with no use of statins or aspirin, use of only statins without aspirin was significantly associated with a risk reduction only in high-grade PCa (Table S4).

### 4 DISCUSSION

Results of this large hospital-based cohort study indicated that statin use might be associated with decreased risk of both low- and high-Gleason grade PCa in a duration- and dose-response mode. Of note, this statin-related PCa risk reduction was observed only when statins had been used for a relatively longer duration and were more pronounced for PCa of a higher Gleason score. Lipophilic statins might have a better anti-PCa effect than hydrophilic statins. These findings add to evidence to elucidate the association of statin use with PCa risk.

A common challenge in studying statin use and PCa risk was “healthy user bias.” Statin users, who might use health services more frequently than nonstatin users, possibly also have more opportunities for PSA screening and therefore have a decreased risk of high-grade PCa. If this explanation holds, the risk of low-grade PCa may increase among statin users. But in our study, statin use was associated with decreased risk of both low- and high-grade PCa. This indicates that the “healthy user bias” may not fully explain the observed association of statin use and PCa risk in our study.

In the current study, statin users had higher prevalence of comorbidities at baseline (Table 1). This is a problem

| TABLE 3 Association of statin use with risk of Gleason score-specific prostate cancer |
|----------------------------------------|-----------------|-----------------|
| **Gleason score of prostate cancer**   | **No statin use** | **Statin use**   |
| <7                                    | 1868            | 440             |
| HR (95% CI)$^a$                       | 1.00            | 0.85 (0.74-0.96) |
| 7 (3 + 4)                             | 224             | 35              |
| HR (95% CI)$^a$                       | 1.00            | 0.62 (0.43-0.90) |
| 7 (4 + 3)                             | 149             | 20              |
| HR (95% CI)$^a$                       | 1.00            | 0.49 (0.29-0.82) |
| 8                                     | 115             | 21              |
| HR (95% CI)$^a$                       | 1.00            | 0.60 (0.37-0.96) |
| 9-10                                  | 97              | 7               |
| HR (95% CI)$^a$                       | 1.00            | 0.24 (0.11-0.54) |

*Using age as time metric in the models adjusted for race, family history of prostate cancer; baseline smoking status, body mass index, hypertension, hyperlipidemia, benign prostatic diseases, diabetes, chronic kidney disease, use of aspirin, angiotensin-converting enzyme inhibitors, insulin, vitamin E/multivitamin, finasteride, metformin, testosterone supplement, selenium, prostate-specific antigen level; as well as atherosclerotic cardiovascular disease and cumulative number of prostate-specific antigen tests as time-dependent variables.

### TABLE 4 Association of statin lipophilicity with risk of overall and Gleason grade-specific prostate cancer

| Statin exposure | Overall | Gleason 2-6 | Gleason 7-10 |
|-----------------|---------|------------|-------------|
|                 | No. of sample | No. of cases | HR (95% CI)$^a$ | No. of cases | HR (95% CI)$^a$ | No. of cases | HR (95% CI)$^a$ |
| No use of statins | 9226      | 2453       | 1.00         | 1868        | 1.00        | 585         | 1.00        |
| Type of statins used |       |            |              |             |             |             |             |
| Only lipophilic  | 3185      | 456        | 0.83 (0.72-0.95) | 384       | 0.86 (0.74-1.01) | 72          | 0.63 (0.48-0.83) |
| Only hydrophilic | 328       | 46         | 0.91 (0.63-1.33) | 40        | 1.04 (0.69-1.57) | 6           | 0.48 (0.20-1.16) |
| Both lipophilic and hydrophilic | 326       | 21         | 0.77 (0.49-1.22) | 16        | 0.80 (0.47-1.36) | 5           | 0.62 (0.25-1.54) |

*Using age as time metric in the models adjusted for race, family history of prostate cancer; baseline smoking status, body mass index, hypertension, hyperlipidemia, benign prostatic diseases, diabetes, chronic kidney disease, use of aspirin, angiotensin-converting enzyme inhibitors, insulin, vitamin E/multivitamin, finasteride, metformin, testosterone supplement, selenium, prostate-specific antigen level; as well as atherosclerotic cardiovascular disease and cumulative number of prostate-specific antigen tests as time-dependent variables.

Abbreviations: CI, confidence interval; HR, hazard ratio.

$^a$Using age as time metric in the models adjusted for race, family history of prostate cancer; baseline smoking status, body mass index, hypertension, hyperlipidemia, benign prostatic diseases, diabetes, chronic kidney disease, use of aspirin, angiotensin-converting enzyme inhibitors, insulin, vitamin E/multivitamin, finasteride, metformin, testosterone supplement, selenium, prostate-specific antigen level; as well as atherosclerotic cardiovascular disease and cumulative number of prostate-specific antigen tests as time-dependent variables.
that was also found in several other population/hospital-based studies of statin use and PCA risk.\textsuperscript{21,22} Elevated serum cholesterol levels and related comorbidities, for example CVD and hypertension, are known to promote PCA initiation.\textsuperscript{23,24} Even so, we found a protective association of statin use with PCA risk after adjustment for comorbidities. In sensitivity analyses stratified by baseline CVD, the statin use-related PCA risk reduction was consistent across those with and without CVD (Table S3). It indicates a low possibility that CVD history, as a major reason for statin prescription, had exaggerated the observed benefits of statin use.

The protective association of statin use with PCA risk is in line with in vitro studies. Mechanistically, statins reduce intracellular and serum cholesterol, thus may affect cell membrane organogenesis, steroidogenesis, and proliferation.\textsuperscript{25} Growth inhibition in prostate-derived cell lines was indeed observed at clinically relevant statin concentrations.\textsuperscript{26,27} In addition, to clarify the overall association of statin use on PCA risk, a further effort is needed to determine whether this association is duration-/dose-dependent. In our study, risks of both low- and high-Gleason grade PCA were observed to decrease with increasing cumulative duration and cumulative dose of statin use ($P_{\text{trend}} < .001$), and significant PCA risk reduction was observed only when statins had been used for a relatively longer duration. This is in agreement with cell culture study which reported that only a long-term statin exposure could induce cell apoptosis, G1 cell cycle arrest, autophagy, and degradation of androgen receptors.\textsuperscript{28} If statins impact PCA risk via the action on lipid metabolism, lipophilicity of statins may be important in determining their cancer-preventive capability.\textsuperscript{29}

In the current study, we only found a significant protective association of lipophilic statins with PCA risk. This is in line with observational and experimental studies\textsuperscript{30,31} which reported a reduced number of colonies in clonogenic assays.\textsuperscript{2}, we speculate that the observed benefit of statin use cannot be fully due to “healthy users bias.” But for specific category of statin use duration, for example <10 month, we cannot rule out the possibility of “healthy user bias,” especially considering patients with a shorter statin use duration are at their early stage of lipid screening, thus they are more likely to be prescribed a PSA testing. But, no increased risk of low-grade PCA was observed for low dose of statin use. Therefore, more studies are needed to replicate this finding and confirm involved mechanisms.

In conclusion, this study indicated that statin use might be associated with decreased risk of both low- and high-Gleason grade PCA, particularly when statins had been used for a relatively longer duration. Also, the statin-related PCA risk reduction was higher for PCA of a higher Gleason score, and lipophilic statins might act better than hydrophilic statins in PCA prevention. More studies are needed to confirm these findings.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**AUTHOR CONTRIBUTIONS**

KW and MP designed the study and conducted the main analysis. All authors participated in interpreting the results and drafting the manuscript. All the authors approved this final version of the manuscript.

**ORCID**

Kai Wang https://orcid.org/0000-0002-5614-5618

**REFERENCES**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.
2. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15:3866-3871.
3. Jahn JL, Giovannucci EL, Stampfer MJ. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era. *Int J Cancer*. 2015;137:2795-2802.

4. Krane LS, Kaul SA, Stricker HJ, Peabody JO, Menon M, Agarwal PK. Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. *J Urol*. 2010;183:118-124.

5. Trialists CT. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. *The Lancet*. 2010;376:1670-1681.

6. Li YC, Park MJ, Ye S‐K, Kim C‐W, Kim Y‐N. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. *Am J Pathol*. 2006;168:1107-1118.

7. Wang K, Chen X, Bird VY, Gerke TA, Manini TM, Prosperi M. Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients’ data with prostatic diseases. *Int J Cancer*. 2017;141:1783-1793.

8. Wang K, Chen X, Gerke TA, Bird VY, Ghayee HK, Prosperi M. BMI trajectories and risk of overall and grade-specific prostate cancer: an observational cohort study among men seen for prostatic conditions. *Cancer Med*. 2018;7:5272-5280.

9. Moon H, Hill MM, Roberts MJ, Gardiner RA, Brown AJ. Statins: protectors or pretenders in prostate cancer? *Trends Endocrinol Metab*. 2014;25:188-196.

10. Dawe DE, Ye X, Czaykowski P, et al. The effect of statin use on the incidence of prostate cancer: a population-based nested case-control study. *Int J Cancer*. 2018;143:190-198.

11. Tan P, Zhang C, Wei S-Y, et al. Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review. *Asian J Androl*. 2017;19:666-671.

12. Stensland K, McBride RB, Leapman M, Hobbs A, Jazayeri SB, Samadi DB. Preoperative statin use associated with lower PSA but similar prostate size and histopathologic outcomes: implications for active surveillance? *Urol J*. 2017;14:3064-3070.

13. Flick ED, Habel LA, Chan KA, et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. *Cancer Epidemiol Biomarkers Prev*. 2007;16:2218-2225.

14. Jespersen CG, Norgaard M, Friis S, Skriver C, Borre M. Statin use and risk of prostate cancer: a Danish population-based case-control study, 1997–2010. *Cancer Epidemiol*. 2014;38:42-47.

15. Majumdar SR, McAlister FA, Eurch DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. *BMJ*. 2006;333:23.

16. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. *Am J Epidemiol*. 2007;166:348-354.

17. WHO. DDD: definition and general considerations. WHO Collaborating Centre for Drug Statistics Methodology. 2016.

18. van Rein N, Carnegie SC, le Cessie S, et al. Statins and risk of bleeding: an analysis to evaluate possible bias due to prevalent users and healthy user aspects. *Am J Epidemiol*. 2016;183:930-936.

19. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. *Am J Epidemiol*. 2003;158:915-920.

20. Penney KL, Stampfer MJ, Jahn JL, et al. Gleason grade progression is uncommon. *Cancer Res*. 2013;73:5163-5168.

21. Mondul AM, Selvin E, De Marzo AM, Freedland SJ, Platz EA. Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001–2004. *Cancer Causes Control*. 2010;21:671-678.

22. Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T. Statins and prostate cancer: molecular and clinical aspects. *Eur J Cancer*. 2011;47:819-830.

23. Kitahara CM, Berrington de Gonzalez A, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. *J Clin Oncol*. 2011;29:1592-1598.

24. Pai P-Y, Hsieh V-R, Wang C-B, et al. Long term antihypertensive drug use and prostate cancer risk: a 9-year population-based cohort analysis. *Int J Cardiol*. 2015;193:1-7.

25. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. *Int J Cancer*. 2008;123:1693-1698.

26. Murtola TJ, Visakorpi T, Lahtela J, Syhala H, Tammela T. Statins and prostate cancer prevention: where we are now, and future directions. *Nat Clin Pract Urol*. 2008;5:376-387.

27. Murtola TJ, Pennanen P, Syhala H, Blauer M, Ylikomi T, Tammela TL. Effects of simvastatin, acetylalsicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. *Prostate*. 2009;69:1017-1023.

28. Costa RA, Fernandes MP, de Souza-Pinto NC, Vercesi AE. Protective effects of l-carnitine and piracetam against mitochondrial permeability transition and PC3 cell necrosis induced by simvastatin. *Eur J Pharmacol*. 2013;701:82‐86.

29. Penley KL, Freeman MR, Solomon KR. Cholesterol and prostate cancer. *Curr Opin Pharmacol*. 2012;12:751-759.

30. Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. *Am J Med*. 2008;121:302-309.

31. Brown M, Hart C, Tawadros T, et al. The differential effects of statins on the metastatic behaviour of prostate cancer. *Br J Cancer*. 2012;106:1689-1696.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Wang K, Gerke TA, Chen X, Prosperi M. Association of statin use with risk of Gleason score-specific prostate cancer: A hospital-based cohort study. *Cancer Med*. 2019;8:7399–7407. [https://doi.org/10.1002/cam4.2500](https://doi.org/10.1002/cam4.2500)